[1]全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告.中国防痨杂志, 2012, 34(8): 485-508.
[2]肖和平, 方勇. 多项措施并举消除结核病传染源. 临床荟萃, 2016, 31(10): 1045-1047.
[3]World Health Organization.Global tuberculosis report 2015.Geneva:World Health Organization,2015.
[4]杜雨华, 苏汝钊, 周惠贤,等. 116例耐多药肺结核治疗转归情况影响因素分析.中国防痨杂志, 2012, 34(1):19-22.
[5]李莉, 孙建胜, 吴云亮. 徐州市完成全球基金耐多药结核病项目全程治疗的耐多药结核病患者治疗效果的影响因素分析. 实用心脑肺血管病杂志, 2015(7):50-54.
[6]WHO Guidelines Approved by the Guidelines Review Committee. Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). Geneva: World Health Organization; 2009.7
[7]北京:中国协和医科大学出版社. 中国结核病防治规划实施工作指南(2008年版) [J]. 2009.7, 52-53.
[8]刘关键, 吴泰相. Meta-分析的森林图及临床意义.中国循证医学杂志, 2004, 4(3): 198-201.
[9]World Health Organization. Acess to the WHO global TB database. Geneva:World Health Organization,2016.
[10]周颖,吴惠忠,陈亮,等.中国耐多药肺结核患者治疗结局的Meta分析.热带医学杂志, 2016, 16(3):325-328.
[11]Raviglione M, Zumla A, Marais B, et al. A sustainable agenda for tuberculosis control and research . Lancet, 2012, 379(9821): 1077-1078.
[12]高会霞,侯军良,张志,等.346例肺结核患者结核分枝杆菌耐药性调查及耐多药结核病影响因素分析.中国防痨杂志, 2015, 37(11):1130-1135.
[13]王铁琼. 120例耐多药肺结核治疗转归情况影响因素分析. 今日健康, 2014,13(10):38.
[14]Unsal E, Güler M, Ofluoglu R, et al. Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis. J Thora Dis, 2013, 5(4): 435-439.
[15]Yadav AK, Mehrotra AK, Agnihotri SP, et al. Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients. Indian J Tuberc, 2016, 63(4): 255-261.
[16]De Vries G, Tsolova S, Anderson LF et al. Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences. Bmc Public Health, 2017, 17(1): 334.
[17]Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication sdverse effects: a case-control study in Lima, Peru. PLoS One, 2011, 6(11):e27610.
[18]于林田.抗结核药品不良反应研究及其应对策略探讨.中国处方药, 2015,13(6):50-51.
[19]Tabarsi P, Chitsaz E, Baghaei P, et al. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microb Drug Resist, 2010, 16(1):81-86.
[20]蒋博峰,马晨晨,陈阳贵,等. 抗结核药物不良反应发生率及其影响因素分析. 中华疾病控制杂志, 2017,21(2):160-163.
[21]Van Deun A, Salim MA, Das AP, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis, 2004, 8(5):560-567.
[22]Sunita S, Amita J, Prasad R, et al. High initial bacillary load in patients with pulmonary tuberculosis: an indicator of drug resistant tuberculosis . J Commun Dis, 2010, 42(4): 241-247.
[23]段琼红, 陈聪, 张正斌,等. 武汉市首次复治涂阳肺结核治疗结局及影响因素分析. 中国防痨杂志, 2013, 35(10):788-792.
[24]Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet, 1999, 353(9157): 969-973.
[25]Kritski AL, Rodrigues de Jesus LS, Andrade MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest, 1997, 111(5):1162-1167.
[26]Choi H, Lee M, Chen RY, et al. Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infect Dis, 2014, 14(1):1-12. |